Dyslipidaemia, characterised as abnormally elevated levels of lipids and lipoproteins in the bloodstream, is a well-established contributor to cardiovascular (CV) disease.1 Elevated levels of a form of dyslipidaemia known as low-density lipoprotein cholesterol (LDL-C), often referred to as "bad cholesterol," significantly raises the risk of atherosclerotic CV events such as coronary artery disease, stroke, and heart failure. The global burden of dyslipidaemia is growing, contributing to approximately 4.4 million deaths annually worldwide.
